Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -26.24% is 82% above its 5-year average of -147.49%, near the high end of its 5-year range (-814.62%–62.00%).
As of the fiscal period ended Tuesday, June 30, 2026. 84.74% above its 12-month average of -171.95%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -26.24%.
RETURN ON EQUITY (ROE)
-26.24%
RETURN ON EQUITY (ROE) AVG TTM
-171.95%
RETURN ON EQUITY (ROE) AVG 3Y
-135.22%
RETURN ON EQUITY (ROE) AVG 5Y
-147.49%
RETURN ON EQUITY (ROE) AVG 10Y
-146.75%
RETURN ON EQUITY (ROE) AVG 15Y
-175.65%
RETURN ON EQUITY (ROE) AVG 20Y
-174.83%
CURRENT VS TTM AVG
+84.74%
CURRENT VS 3Y AVG
+80.60%
CURRENT VS 5Y AVG
+82.21%
CURRENT VS 10Y AVG
+82.12%
CURRENT VS 15Y AVG
+85.06%
CURRENT VS 20Y AVG
+84.99%
SECTOR MEDIAN · HEALTHCARE
-40.30%
median of 668 covered companies
CURRENT VS SECTOR MEDIAN
+34.91%
vs the sector median at left
Palisade Bio, Inc.
Market Cap
$261.24M
Return on Equity (ROE)
-26.24%
TTM Avg
-171.95%
3Y Avg
-135.22%
5Y Avg
-147.49%
Market Cap
$261.87M
Return on Equity (ROE)
-37.12%
TTM Avg
-62.34%
3Y Avg
-32.67%
5Y Avg
8.91%
Market Cap
$260.03M
Return on Equity (ROE)
-124.67%
TTM Avg
-101.06%
3Y Avg
-69.44%
5Y Avg
-56.33%
Market Cap
$257.79M
Return on Equity (ROE)
-2.76%
TTM Avg
-22.10%
3Y Avg
-22.09%
5Y Avg
-15.95%
Market Cap
$266.05M
Return on Equity (ROE)
-39.55%
TTM Avg
-28.46%
3Y Avg
-79.02%
5Y Avg
-63.95%
Market Cap
$266.10M
Return on Equity (ROE)
-15.46%
TTM Avg
-12.46%
3Y Avg
-4.29%
5Y Avg
-4.49%
Market Cap
$266.17M
Return on Equity (ROE)
-38.33%
TTM Avg
-61.68%
3Y Avg
-393.03%
5Y Avg
-278.88%
Market Cap
$267.03M
Return on Equity (ROE)
-184.27%
TTM Avg
-57.34%
3Y Avg
-61.84%
5Y Avg
-87.31%
Market Cap
$254.41M
Return on Equity (ROE)
-47.25%
TTM Avg
-42.23%
3Y Avg
-50.43%
5Y Avg
-29.25%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Palisade Bio, Inc. (PALI) | $261.24M | -26.24% | -171.95% | -135.22% | -147.49% |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $261.87M | -37.12% | -62.34% | -32.67% | 8.91% |
| AC Immune S.A. (ACIU)vs › | $260.03M | -124.67% | -101.06% | -69.44% | -56.33% |
| Anika Therapeutics, Inc. (ANIK)vs › | $257.79M | -2.76% | -22.10% | -22.09% | -15.95% |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $266.05M | -39.55% | -28.46% | -79.02% | -63.95% |
| OraSure Technologies, Inc. (OSUR)vs › | $266.10M | -15.46% | -12.46% | -4.29% | -4.49% |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $266.17M | -38.33% | -61.68% | -393.03% | -278.88% |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $267.03M | -184.27% | -57.34% | -61.84% | -87.31% |
| Century Therapeutics, Inc. (IPSC)vs › | $254.41M | -47.25% | -42.23% | -50.43% | -29.25% |
| Sol-Gel Technologies Ltd. (SLGL)vs › | $249.78M | -33.97% | -31.77% | -42.34% | -36.86% |
ROE
-26.2%
ROA
-25.1%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -26.24% |
| 2026-03-31 | -18.96% |
| 2025-12-31 | -12.97% |
| 2025-09-30 | -349.50% |
| 2025-06-30 | -452.10% |
| 2025-03-31 | -246.50% |
| 2024-12-31 | -192.71% |
| 2024-09-30 | -212.85% |
| 2024-06-30 | -142.47% |
| 2024-03-31 | -134.01% |
| 2023-12-31 | -108.72% |
| 2023-09-30 | -92.66% |
| 2023-06-30 | -85.09% |
| 2023-03-31 | -90.17% |
| 2022-12-31 | -114.27% |
| 2022-09-30 | -76.16% |
| 2022-06-30 | 62.00% |
| 2022-03-31 | -559.08% |
| 2021-12-31 | -361.38% |
| 2021-09-30 | -814.62% |
| 2020-06-30 | -54.56% |
| 2020-03-31 | -84.63% |
| 2019-12-31 | -178.97% |
| 2019-09-30 | -94.20% |
| 2019-06-30 | -341.43% |
| 2019-03-31 | -180.05% |
| 2018-12-31 | -81.39% |
| 2018-09-30 | -176.82% |
| 2018-06-30 | -100.79% |
| 2018-03-31 | -155.08% |
| 2017-12-31 | -183.98% |
| 2017-09-30 | -153.45% |
| 2017-06-30 | -296.80% |
| 2017-03-31 | -225.32% |
| 2016-12-31 | -186.00% |
| 2015-12-31 | -420.83% |
| 2015-09-30 | -243.09% |
| 2015-06-30 | -140.71% |
| 2015-03-31 | -112.40% |
| 2014-12-31 | -127.70% |
| 2014-09-30 | -97.72% |
| 2014-06-30 | -94.30% |
| 2014-03-31 | -82.39% |
| 2013-12-31 | -235.58% |
| 2013-09-30 | -232.78% |
| 2013-06-30 | -342.98% |
| 2013-03-31 | -197.73% |
| 2012-12-31 | -145.16% |
| 2012-09-30 | -109.50% |
| 2012-06-30 | -425.84% |
| 2012-03-31 | -261.76% |
| 2011-12-31 | -754.19% |
| 2011-09-30 | -325.48% |
| 2011-06-30 | -214.18% |
| 2011-03-31 | -169.69% |
| 2010-12-31 | -234.11% |
| 2010-09-30 | -216.27% |
| 2010-06-30 | -180.27% |
| 2010-03-31 | -359.13% |
| 2008-12-31 | -281.47% |
| 2008-09-30 | -227.38% |
| 2008-06-30 | -133.98% |
| 2008-03-31 | -91.43% |
| 2007-12-31 | -90.69% |
| 2007-09-30 | -115.02% |
| 2007-06-30 | -80.43% |
| 2007-03-31 | -50.83% |
